{"title":"Ahmed青光眼瓣膜治疗新生血管性青光眼(AOS论文)。","authors":"Peter A Netland","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the results of Ahmed glaucoma valve surgery in neovascular glaucoma and control patients.</p><p><strong>Methods: </strong>In this retrospective comparative study, we reviewed 76 eyes of 76 patients, comparing the surgical outcomes in control patients (N=38) to matched neovascular glaucoma patients (N=38). Success was defined as intraocular pressure (IOP) > or =6 mm Hg and < or =21 mm Hg, without further glaucoma surgery, and without loss of light perception.</p><p><strong>Results: </strong>Average follow-up for control and neovascular glaucoma patients was 18.4 and 17.4 months, respectively (P = .550). At last follow-up, mean IOP was 16.2 +/- 5.2 mm Hg and 15.5 +/- 12.5 mm Hg (P = .115) in control and neovascular glaucoma patients, respectively. Life-table analysis showed a significantly lower success for neovascular glaucoma patients compared with controls (P = .0096), with success at 1 year of 89.2% and 73.1%, at 2 years of 81.8% and 61.9%, and at 5 years of 81.8% and 20.6% for control and neovascular glaucoma eyes, respectively. Cox proportional hazards regression analysis showed neovascular glaucoma as a risk factor for surgical failure (odds ratio, 5.384, 95% CI, 1.22-23.84, P = .027). Although IOP control and complications were comparable between the two groups, visual outcomes were worse in neovascular glaucoma patients, with 9 eyes (23.7%) with neovascular glaucoma compared with no controls losing light perception vision (P = .002). The majority with loss of vision (5 of 9) had successful control of IOP during the postoperative period.</p><p><strong>Conclusion: </strong>Neovascular glaucoma patients have greater risk of surgical failure after Ahmed glaucoma valve surgery compared with controls. Despite improved mean IOP with drainage implants, visual outcomes may be poor, possibly due to progression of underlying disease.</p>","PeriodicalId":23166,"journal":{"name":"Transactions of the American Ophthalmological Society","volume":"107 ","pages":"325-42"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814575/pdf/1545-6110_v107_p325.pdf","citationCount":"0","resultStr":"{\"title\":\"The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).\",\"authors\":\"Peter A Netland\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the results of Ahmed glaucoma valve surgery in neovascular glaucoma and control patients.</p><p><strong>Methods: </strong>In this retrospective comparative study, we reviewed 76 eyes of 76 patients, comparing the surgical outcomes in control patients (N=38) to matched neovascular glaucoma patients (N=38). Success was defined as intraocular pressure (IOP) > or =6 mm Hg and < or =21 mm Hg, without further glaucoma surgery, and without loss of light perception.</p><p><strong>Results: </strong>Average follow-up for control and neovascular glaucoma patients was 18.4 and 17.4 months, respectively (P = .550). At last follow-up, mean IOP was 16.2 +/- 5.2 mm Hg and 15.5 +/- 12.5 mm Hg (P = .115) in control and neovascular glaucoma patients, respectively. Life-table analysis showed a significantly lower success for neovascular glaucoma patients compared with controls (P = .0096), with success at 1 year of 89.2% and 73.1%, at 2 years of 81.8% and 61.9%, and at 5 years of 81.8% and 20.6% for control and neovascular glaucoma eyes, respectively. Cox proportional hazards regression analysis showed neovascular glaucoma as a risk factor for surgical failure (odds ratio, 5.384, 95% CI, 1.22-23.84, P = .027). Although IOP control and complications were comparable between the two groups, visual outcomes were worse in neovascular glaucoma patients, with 9 eyes (23.7%) with neovascular glaucoma compared with no controls losing light perception vision (P = .002). The majority with loss of vision (5 of 9) had successful control of IOP during the postoperative period.</p><p><strong>Conclusion: </strong>Neovascular glaucoma patients have greater risk of surgical failure after Ahmed glaucoma valve surgery compared with controls. Despite improved mean IOP with drainage implants, visual outcomes may be poor, possibly due to progression of underlying disease.</p>\",\"PeriodicalId\":23166,\"journal\":{\"name\":\"Transactions of the American Ophthalmological Society\",\"volume\":\"107 \",\"pages\":\"325-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814575/pdf/1545-6110_v107_p325.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transactions of the American Ophthalmological Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transactions of the American Ophthalmological Society","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:评价艾哈迈德青光眼瓣膜手术治疗新生血管性青光眼和对照组患者的效果。方法:回顾性比较研究76例患者的76只眼,比较对照组(N=38)和匹配的新生血管性青光眼患者(N=38)的手术结果。成功的定义是眼压(IOP) >或=6 mm Hg和<或=21 mm Hg,没有进一步的青光眼手术,没有光感知丧失。结果:对照组和新生血管性青光眼患者的平均随访时间分别为18.4个月和17.4个月(P = 0.550)。最后随访时,对照组和新生血管性青光眼患者的平均IOP分别为16.2 +/- 5.2 mm Hg和15.5 +/- 12.5 mm Hg (P = 0.115)。生命表分析显示,与对照组相比,新生血管性青光眼患者的治疗成功率明显降低(P = 0.0096),对照组和新生血管性青光眼患者的治疗成功率分别为89.2%和73.1%,2年和5年分别为81.8%和61.9%,5年分别为81.8%和20.6%。Cox比例风险回归分析显示新生血管性青光眼是手术失败的危险因素(优势比为5.384,95% CI为1.22 ~ 23.84,P = 0.027)。虽然两组的IOP控制和并发症相当,但新生血管性青光眼患者的视力结果更差,与无对照组相比,有9只(23.7%)新生血管性青光眼患者失去光感视力(P = 0.002)。大多数视力丧失患者(5 / 9)术后成功控制了IOP。结论:与对照组相比,Ahmed青光眼瓣膜手术后新生血管性青光眼患者手术失败的风险更高。尽管引流植入物改善了平均IOP,但可能由于潜在疾病的进展,视力结果可能较差。
The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).
Purpose: To evaluate the results of Ahmed glaucoma valve surgery in neovascular glaucoma and control patients.
Methods: In this retrospective comparative study, we reviewed 76 eyes of 76 patients, comparing the surgical outcomes in control patients (N=38) to matched neovascular glaucoma patients (N=38). Success was defined as intraocular pressure (IOP) > or =6 mm Hg and < or =21 mm Hg, without further glaucoma surgery, and without loss of light perception.
Results: Average follow-up for control and neovascular glaucoma patients was 18.4 and 17.4 months, respectively (P = .550). At last follow-up, mean IOP was 16.2 +/- 5.2 mm Hg and 15.5 +/- 12.5 mm Hg (P = .115) in control and neovascular glaucoma patients, respectively. Life-table analysis showed a significantly lower success for neovascular glaucoma patients compared with controls (P = .0096), with success at 1 year of 89.2% and 73.1%, at 2 years of 81.8% and 61.9%, and at 5 years of 81.8% and 20.6% for control and neovascular glaucoma eyes, respectively. Cox proportional hazards regression analysis showed neovascular glaucoma as a risk factor for surgical failure (odds ratio, 5.384, 95% CI, 1.22-23.84, P = .027). Although IOP control and complications were comparable between the two groups, visual outcomes were worse in neovascular glaucoma patients, with 9 eyes (23.7%) with neovascular glaucoma compared with no controls losing light perception vision (P = .002). The majority with loss of vision (5 of 9) had successful control of IOP during the postoperative period.
Conclusion: Neovascular glaucoma patients have greater risk of surgical failure after Ahmed glaucoma valve surgery compared with controls. Despite improved mean IOP with drainage implants, visual outcomes may be poor, possibly due to progression of underlying disease.